This study performed an external validation of a melanoma sentinel lymph node metastasis risk prediction tool. The validated tool demonstrated good discrimination in predicting sentinel node positivity, supporting its clinical use for informed decision-making about SLNB in melanoma patients.

Validated risk prediction tools can help clinicians and patients make more informed decisions about whether to proceed with SLNB.

External validation confirmed that the melanoma SLNB risk tool performs well across diverse patient populations.